Characteristics | Ezetimibe /simvastatin (n = 25) | Rosuvastatin (n = 25) | p-value |
---|---|---|---|
Age, years | 62.5 ± 7.4 | 59.2 ± 8.8 | 0.154 |
Men | 22 (88.0%) | 21 (84.0%) | 0.684 |
Current smoker | 4 (16.0%) | 5 (20.0%) | 0.713 |
Diabetes mellitus | 2 (8.0%) | 3 (12.0%) | 0.637 |
Hypertension | 17 (68.0%) | 10 (40.0%) | 0.047 |
Diagnosis | 0.301 | ||
STEMI | 19 (76.0%) | 19 (76.0%) | |
NSTE-ACS | 6 (2.0%) | 6 (24.0%) | |
Culprit artery of ACS | 0.345 | ||
Left anterior descending coronary | 17 (68.0%) | 16 (64.0%) | |
Left circumflex coronary | 2 (8.0%) | 0 (0%) | |
Right coronary | 6 (24.0%) | 8 (32.0%) | |
Ramus intermedius | 0 (0%) | 1 (4.0%) | |
Culprit lesion PCI | 24 (97.5%) | 25 (100%) | 0.848 |
Left ventricular ejection fraction (%) | 52.9 ± 8.2 | 53.9 ± 73 | 0.718 |
Medications at the time of follow-up | |||
Aspirin | 25 (100%) | 25 (100%) | 1.0 |
P2Y12 inhibitors | 25 (100.0%) | 25 (100.0%) | 1.0 |
β-blockers | 22 (88.0%) | 19 (76.0%) | 0.269 |
Angiotensin II receptor blocker | 12 (48.0%) | 13 (52.0%) | 0.777 |
Calcium channel blocker | 13 (52.0%) | 12 (48.0%) | 0.777 |